Trusted Resources: News & Meetings
Latest announcements and gatherings
Takeda to Commercialize Next-Generation Hunter Syndrome Therapy Through Collaboration With JCR Pharmaceuticals
Takeda Pharmaceutical Company Limited and JCR Pharmaceuticals Co., Ltd. announced a geographically-focused exclusive collaboration and license agreement to commercialize JR-141 (INN: pabinafusp alfa), an investigational, next-generation recombinant fusion protein of an antibody against the human transferrin receptor and iduronate-2-sulfatase (IDS) enzyme for the treatment of Hunter syndrome (also known as Mucopolysaccharidosis type II or MPS II).
Hunter syndrome is caused by a deficiency of IDS and manifests in different forms. JR-141, applied with J-Brain Cargo®, JCR’s proprietary blood-brain barrier (BBB) technology, is engineered to transport the therapeutic enzyme across the BBB to directly reach the brain and address both the somatic and neuronopathic manifestations of the disease, which can lead to progressive cognitive decline.
BookmarkRelated Content
-
Q&A Coronavirus and Sanfilippo Syndrome: Dr. Heather Lauhttps://www.youtube.com/watch?v=Dn3XZiHA...
-
Drug Delivery for Neuronopathic Lysosomal Storage Diseases: Evolving Roles of the Blood Brain Barrier and Cerebrospi...Whereas significant strides have been ma...
-
Raymond Y. Wang, MDRaymond Wang, M.D. is the Director of th...
-
University of Minnesota – Mucopolysaccharidosis (MPS) CenterOur MPS Center is internationally recogn...
-
Advocacy Groups Unveil ‘Roadmap’ for Sanfilippo Research, CareA coalition of patient advocacy organiza...
-
Hurler Holes in Hunter SyndromeA 16-year-old male presented to our hosp...
-
Hunter Syndrome: OverviewHunter syndrome is a very rare, inherite...
Powered by
